3D tissue-engineered model of Ewing's sarcoma

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 155-171

  Lamhamedi Cherradi, Salah Eddine ^a   Santoro, Marco ^a,b   Ramammoorthy, Vandhana ^a   Menegaz, Brian A ^a   Bartholomeusz, Geoffrey ^a   Iles, Lakesla R ^a   Amin, Hesham M ^a   Livingston, J Andrew ^a   Mikos, Antonios G ^b   Ludwig, Joseph A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Rice University   (United States)

Author keywords

3D; ECM; Ewing's sarcoma; MCTS; Preclinical testing; Scaffolds; Tissue engineering; Tumor model

Indexed keywords

BIOMIMETIC PROCESSES; DRUG THERAPY; ENZYME INHIBITION; MILITARY ELECTRONIC COUNTERMEASURES; SCAFFOLDS; SCAFFOLDS (BIOLOGY);

3D; EWING'S SARCOMA; MCTS; PRE-CLINICAL TESTING; TUMOR MODELS;

TUMORS;

ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOMIMETICS; BONE TUMOR; BRAIN CANCER; CANCER CELL; CANCER RESEARCH; CARCINOGENESIS; CELL MIGRATION; COLON CANCER; DRUG MECHANISM; EPIGENETICS; EWING SARCOMA; EXTRACELLULAR MATRIX; HUMAN; MONOLAYER CULTURE; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; RELIABILITY; REVIEW; SITE DIRECTED MUTAGENESIS; TISSUE ENGINEERING; TUMOR SPHEROID; ANIMAL; BIOLOGICAL MODEL; BONE NEOPLASMS; CHILD; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SARCOMA, EWING;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HUMANS; MODELS, BIOLOGICAL; PRECISION MEDICINE; SARCOMA, EWING; TISSUE ENGINEERING;

EID: 84919468933     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.07.012     Document Type: Review

References (233)

1. Balamuth N.J., Womer R.B. Ewing's sarcoma. Lancet Oncol. 2010, 11:184-192.
2. Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J. Clin. 1972, 22:95-98.
3. Angervall L., Enzinger F.M. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 1975, 36:240-251.
4. Askin F.B., Rosai J., Sibley R.K., Dehner L.P., McAlister W.H. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979, 43:2438-2451.
5. Jaffe R., Santamaria M., Yunis E.J., Tannery N.H., Agostini R.M., Medina J., Goodman M. The neuroectodermal tumor of bone. Am. J. Surg. Pathol. 1984, 8:885-898.
6. de Alava E., Gerald W.L. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J. Clin. Oncol. 2000, 18:204-213.
7. Ordonez J.L., Osuna D., Herrero D., de Alava E., Madoz-Gurpide J. Advances in Ewing's sarcoma research: where are we now and what lies ahead?. Cancer Res. 2009, 69:7140-7150.
8. Kauer M., Ban J., Kofler R., Walker B., Davis S., Meltzer P., Kovar H. A molecular function map of Ewing's sarcoma. PLoS ONE 2009, 4:e5415.
9. Fletcher C.D.M., World Health Organization, International Agency for Research on Cancer WHO Classification of Tumours of Soft Tissue and Bone 2013, IARC Press, Lyon. 4th ed.
10. Esiashvili N., Goodman M., Marcus R.B. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J. Pediatr. Hematol. Oncol. 2008, 30:425-430.
11. Lin P.P., Wang Y., Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma, Sarcoma, 2011 2011.
12. Parkin D.M., Stiller C.A., Nectoux J. International variations in the incidence of childhood bone tumours. Int. J. Cancer J. Int. Cancer 1993, 53:371-376.
13. Riggi N., Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett. 2007, 254:1-10.
14. Parkin D.M., Stiller C.A., Nectoux J. International variations in the incidence of childhood bone tumours. Int. J. Cancer 1993, 53:371-376.
15. Ludwig J.A. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr. Opin. Oncol. 2008, 20:412-418.
16. Skubitz K.M., D'Adamo D.R. Sarcoma. Mayo Clin. Proc. Mayo Clin. 2007, 82:1409-1432.
17. Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C., Hoffmann F., Trumpp A., Stamenkovic I. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, 65:11459-11468.
18. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11:421-429.
19. Meltzer P.S. Is Ewing's sarcoma a stem cell tumor?. Cell Stem Cell 2007, 1:13-15.
20. Riggi N., Suva M.L., Suva D., Cironi L., Provero P., Tercier S., Joseph J.M., Stehle J.C., Baumer K., Kindler V., Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008, 68:2176-2185.
21. Miyagawa Y., Okita H., Nakaijima H., Horiuchi Y., Sato B., Taguchi T., Toyoda M., Katagiri Y.U., Fujimoto J., Hata J., Umezawa A., Kiyokawa N. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol. Cell. Biol. 2008, 28:2125-2137.
22. Desmaze C., Zucman J., Delattre O., Thomas G., Aurias A. Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosom. Cancer 1992, 5:30-34.
23. Zucman J., Delattre O., Desmaze C., Plougastel B., Joubert I., Melot T., Peter M., De Jong P., Rouleau G., Aurias A., et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosom. Cancer 1992, 5:271-277.
24. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., Kovar H., Joubert I., de Jong P., Rouleau G., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992, 359:162-165.
25. Sorensen P.H., Lessnick S.L., Lopez-Terrada D., Liu X.F., Triche T.J., Denny C.T. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 1994, 6:146-151.
26. Jeon I.S., Davis J.N., Braun B.S., Sublett J.E., Roussel M.F., Denny C.T., Shapiro D.N. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995, 10:1229-1234.
27. Urano F., Umezawa A., Yabe H., Hong W., Yoshida K., Fujinaga K., Hata J. Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis. Jpn. J. Cancer Res.: Gann 1998, 89:703-711.
28. Peter M., Couturier J., Pacquement H., Michon J., Thomas G., Magdelenat H., Delattre O. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997, 14:1159-1164.
29. Delattre O., Zucman J., Melot T., Garau X.S., Zucker J.M., Lenoir G.M., Ambros P.F., Sheer D., Turc-Carel C., Triche T.J., et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 1994, 331:294-299.
30. Shing D.C., McMullan D.J., Roberts P., Smith K., Chin S.F., Nicholson J., Tillman R.M., Ramani P., Cullinane C., Coleman N. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 2003, 63:4568-4576.
31. Mastrangelo T., Modena P., Tornielli S., Bullrich F., Testi M.A., Mezzelani A., Radice P., Azzarelli A., Pilotti S., Croce C.M., Pierotti M.A., Sozzi G. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 2000, 19:3799-3804.
32. Sadri N., Barroeta J., Pack S.D., Abdullaev Z., Chatterjee B., Puthiyaveettil R., Brooks J.S., Barr F.G., Zhang P.J. Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion. Virchows Arch. 2014, 465:233-239.
33. Toretsky J.A., Erkizan V., Levenson A., Abaan O.D., Parvin J.D., Cripe T.P., Rice A.M., Lee S.B., Uren A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 2006, 66:5574-5581.
34. Owen L.A., Kowalewski A.A., Lessnick S.L. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 2008, 3:e1965.
35. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4:361-370.
36. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021.
37. Herrero-Martin D., Osuna D., Ordonez J.L., Sevillano V., Martins A.S., Mackintosh C., Campos M., Madoz-Gurpide J., Otero-Motta A.P., Caballero G., Amaral A.T., Wai D.H., Braun Y., Eisenacher M., Schaefer K.L., Poremba C., de Alava E. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br. J. Cancer 2009, 101:80-90.
38. Hahm K.B., Cho K., Lee C., Im Y.H., Chang J., Choi S.G., Sorensen P.H., Thiele C.J., Kim S.J. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat. Genet. 1999, 23:222-227.
39. Ban J., Bennani-Baiti I.M., Kauer M., Schaefer K.L., Poremba C., Jug G., Schwentner R., Smrzka O., Muehlbacher K., Aryee D.N., Kovar H. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res. 2008, 68:7100-7109.
40. Beauchamp E., Bulut G., Abaan O., Chen K., Merchant A., Matsui W., Endo Y., Rubin J.S., Toretsky J., Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J. Biol. Chem. 2009, 284:9074-9082.
41. Navarro D., Agra N., Pestana A., Alonso J., Gonzalez-Sancho J.M. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis 2010, 31:394-401.
42. Fuchs B., Inwards C.Y., Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin. Cancer Res. 2004, 10:1344-1353.
43. Dalal S., Berry A.M., Cullinane C.J., Mangham D.C., Grimer R., Lewis I.J., Johnston C., Laurence V., Burchill S.A. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:2364-2378.
44. Chaturvedi A., Hoffman L.M., Welm A.L., Lessnick S.L., Beckerle M.C. The EWS/FLI oncogene drives changes in cellular morphology, adhesion, and migration in Ewing sarcoma. Genes Cancer 2012, 3:102-116.
45. Pampaloni F., Reynaud E.G., Stelzer E.H. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 2007, 8:839-845.
46. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 2001, 294:1708-1712.
47. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., Sausville E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84:1424-1431.
48. Voskoglou-Nomikos T., Pater J.L., Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 2003, 9:4227-4239.
49. Bhogal N. Immunotoxicity and immunogenicity of biopharmaceuticals: design concepts and safety assessment. Curr. Drug Saf. 2010, 5:293-307.
50. Bid H.K., London C.A., Gao J., Zhong H., Hollingsworth R.E., Fernandez S., Mo X., Houghton P.J. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clin. Cancer Res. 2013, 19:2984-2994.
51. Kolb E.A., Gorlick R., Maris J.M., Keir S.T., Morton C.L., Wu J., Wozniak A.W., Smith M.A., Houghton P.J. Combination testing (stage 2) of the anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 2012, 58:729-735.
52. Siolas D., Hannon G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013, 73:5315-5319.
53. Kang H.G., Jenabi J.M., Zhang J., Keshelava N., Shimada H., May W.A., Ng T., Reynolds C.P., Triche T.J., Sorensen P.H. E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007, 67:3094-3105.
54. Fong E.L., Lamhamedi-Cherradi S.E., Burdett E., Ramamoorthy V., Lazar A.J., Kasper F.K., Farach-Carson M.C., Vishwamitra D., Demicco E.G., Menegaz B.A., Amin H.M., Mikos A.G., Ludwig J.A. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6500-6505.
55. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
56. Bernstein P., Dong M., Corbeil D., Gelinsky M., Gunther K.P., Fickert S. Pellet culture elicits superior chondrogenic redifferentiation than alginate-based systems. Biotechnol. Prog. 2009, 25:1146-1152.
57. Bell E., Ivarsson B., Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:1274-1278.
58. Nirmalanandhan V.S., Duren A., Hendricks P., Vielhauer G., Sittampalam G.S. Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev. Technol. 2010, 8:581-590.
59. Xu X., Prestwich G.D. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010, 116:1739-1750.
60. Butcher J.T., Nerem R.M. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. Tissue Eng. 2006, 12:905-915.
61. Van Hoof D., Braam S.R., Dormeyer W., Ward-van Oostwaard D., Heck A.J., Krijgsveld J., Mummery C.L. Feeder-free monolayer cultures of human embryonic stem cells express an epithelial plasma membrane protein profile. Stem Cells 2008, 26:2777-2781.
62. Chambers K.F., Pearson J.F., Aziz N., O'Toole P., Garrod D., Lang S.H. Stroma regulates increased epithelial lateral cell adhesion in 3D culture: a role for actin/cadherin dynamics. PLoS ONE 2011, 6:e18796.
63. Rak J., Mitsuhashi Y., Erdos V., Huang S.N., Filmus J., Kerbel R.S. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J. Cell Biol. 1995, 131:1587-1598.
64. Hamilton G. Multicellular spheroids as an in vitro tumor model. Cancer Lett. 1998, 131:29-34.
65. Inch W.R., McCredie J.A., Sutherland R.M. Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth 1970, 34:271-282.
66. Sutherland R.M., McCredie J.A., Inch W.R. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst. 1971, 46:113-120.
67. Myatt S.S., Redfern C.P., Burchill S.A. p38MAPK-dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:3136-3148.
68. Timmins N.E., Nielsen L.K. Generation of multicellular tumor spheroids by the hanging-drop method. Methods Mol. Med. 2007, 140:141-151.
69. Kelm J.M., Timmins N.E., Brown C.J., Fussenegger M., Nielsen L.K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol. Bioeng. 2003, 83:173-180.
70. Wu L.Y., Di Carlo D., Lee L.P. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomed. Microdevices 2008, 10:197-202.
71. Kunz-Schughart L.A. Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol. Int. 1999, 23:157-161.
72. Friedrich J., Ebner R., Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int. J. Radiat. Biol. 2007, 83:849-871.
73. Chang T.T., Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng. A 2009, 15:559-567.
74. Cody N.A., Zietarska M., Filali-Mouhim A., Provencher D.M., Mes-Masson A.M., Tonin P.N. Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. BMC Med. Genet. 2008, 1:34.
75. Gaedtke L., Thoenes L., Culmsee C., Mayer B., Wagner E. Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. J. Proteome Res. 2007, 6:4111-4118.
76. Shimada M., Yamashita Y., Tanaka S., Shirabe K., Nakazawa K., Ijima H., Sakiyama R., Fukuda J., Funatsu K., Sugimachi K. Characteristic gene expression induced by polyurethane foam/spheroid culture of hepatoma cell line, Hep G2 as a promising cell source for bioartificial liver. Hepato-Gastroenterology 2007, 54:814-820.
77. Timmins N.E., Dietmair S., Nielsen L.K. Hanging-drop multicellular spheroids as a model of tumour angiogenesis. Angiogenesis 2004, 7:97-103.
78. Yamashita Y., Shimada M., Harimoto N., Tanaka S., Shirabe K., Ijima H., Nakazawa K., Fukuda J., Funatsu K., Maehara Y. cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells. Cell Transplant. 2004, 13:793-799.
79. Zietarska M., Maugard C.M., Filali-Mouhim A., Alam-Fahmy M., Tonin P.N., Provencher D.M., Mes-Masson A.M. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol. Carcinog. 2007, 46:872-885.
80. Lawlor E.R., Scheel C., Irving J., Sorensen P.H. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 2002, 21:307-318.
81. Dufau I., Frongia C., Sicard F., Dedieu L., Cordelier P., Ausseil F., Ducommun B., Valette A. Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 2012, 12:15.
82. Ivascu A., Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J. Biomol. Screen. 2006, 11:922-932.
83. Rodriguez-Enriquez S., Gallardo-Perez J.C., Aviles-Salas A., Marin-Hernandez A., Carreno-Fuentes L., Maldonado-Lagunas V., Moreno-Sanchez R. Energy metabolism transition in multi-cellular human tumor spheroids. J. Cell. Physiol. 2008, 216:189-197.
84. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 2009, 4:309-324.
85. Desoize B., Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit. Rev. Oncol. Hematol. 2000, 36:193-207.
86. Villaverde M.S., Gil-Cardeza M.L., Glikin G.C., Finocchiaro L.M. Interferon-beta lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids. Cancer Gene Ther. 2012, 19:508-516.
87. Awad O., Yustein J.T., Shah P., Gul N., Katuri V., O'Neill A., Kong Y., Brown M.L., Toretsky J.A., Loeb D.M. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS ONE 2010, 5:e13943.
88. Strauss S.J., Ng T., Mendoza-Naranjo A., Whelan J., Sorensen P.H. Understanding micrometastatic disease and Anoikis resistance in Ewing family of tumors and osteosarcoma. Oncologist 2010, 15:627-635.
89. Holmes T.D., El-Sherbiny Y.M., Davison A., Clough S.L., Blair G.E., Cook G.P. A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells. J. Immunol. 2011, 186:1538-1545.
90. Kailayangiri S., Altvater B., Meltzer J., Pscherer S., Luecke A., Dierkes C., Titze U., Leuchte K., Landmeier S., Hotfilder M., Dirksen U., Hardes J., Gosheger G., Juergens H., Rossig C. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br. J. Cancer 2012, 106:1123-1133.
91. Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature 2013, 501:373-379.
92. Takebe T., Sekine K., Enomura M., Koike H., Kimura M., Ogaeri T., Zhang R.R., Ueno Y., Zheng Y.W., Koike N., Aoyama S., Adachi Y., Taniguchi H. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013, 499:481-484.
93. Xia Y., Nivet E., Sancho-Martinez I., Gallegos T., Suzuki K., Okamura D., Wu M.Z., Dubova I., Esteban C.R., Montserrat N., Campistol J.M., Izpisua Belmonte J.C. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat. Cell Biol. 2013, 15:1507-1515.
94. Chapman H.A., Li X., Alexander J.P., Brumwell A., Lorizio W., Tan K., Sonnenberg A., Wei Y., Vu T.H. Integrin alpha6beta4 identifies an adult distal lung epithelial population with regenerative potential in mice. J. Clin. Invest. 2011, 121:2855-2862.
95. Reddy K., Zhou Z., Jia S.F., Lee T.H., Morales-Arias J., Cao Y., Kleinerman E.S. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int. J. Cancer 2008, 123:831-837.
96. Lee T.H., Bolontrade M.F., Worth L.L., Guan H., Ellis L.M., Kleinerman E.S. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int. J. Cancer J. Int. Cancer 2006, 119:839-846.
97. Benini S., Perbal B., Zambelli D., Colombo M.P., Manara M.C., Serra M., Parenza M., Martinez V., Picci P., Scotlandi K. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 2005, 24:4349-4361.
98. Roomi M.W., Ivanov V., Kalinovsky T., Niedzwiecki A., Rath M. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1. Oncol. Rep. 2005, 13:253-257.
99. Zhou Z., Wang J., Cao R., Morita H., Soininen R., Chan K.M., Liu B., Cao Y., Tryggvason K. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 2004, 64:4699-4702.
100. Carpenter P.M., Dao A.V., Arain Z.S., Chang M.K., Nguyen H.P., Arain S., Wang-Rodriguez J., Kwon S.Y., Wilczynski S.P. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Mol. Cancer Res.: MCR 2009, 7:462-475.
101. Lee J., Cuddihy M.J., Kotov N.A. Three-dimensional cell culture matrices: state of the art. Tissue Eng. B Rev. 2008, 14:61-86.
102. Miyamoto H., Murakami T., Tsuchida K., Sugino H., Miyake H., Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004, 28:38-44.
103. Jedeszko C., Sameni M., Olive M.B., Moin K., Sloane B.F. Visualizing protease activity in living cells: from two dimensions to four dimensions. Current Protocols in Cell Biology 2008, Chapter 4, (Unit 4 20). J.S. Bonifacino (Ed.).
104. Moss N.M., Liu Y., Johnson J.J., Debiase P., Jones J., Hudson L.G., Munshi H.G., Stack M.S. Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol. Cancer Res.: MCR 2009, 7:809-820.
105. Sabeh F., Shimizu-Hirota R., Weiss S.J. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185:11-19.
106. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114:33-45.
107. Cavallo-Medved D., Rudy D., Blum G., Bogyo M., Caglic D., Sloane B.F. Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp. Cell Res. 2009, 315:1234-1246.
108. Prestwich G.D. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc. Chem. Res. 2008, 41:139-148.
109. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
110. Bissell M.J., Labarge M.A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?. Cancer Cell 2005, 7:17-23.
111. Wiseman B.S., Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049.
112. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
113. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.P., Gray J.W., Pinkel D., Bissell M.J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
114. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
115. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
116. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
117. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
118. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9:285-293.
119. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004, 16:558-564.
120. Genis L., Gonzalo P., Tutor A.S., Galvez B.G., Martinez-Ruiz A., Zaragoza C., Lamas S., Tryggvason K., Apte S.S., Arroyo A.G. Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells. Blood 2007, 110:2916-2923.
121. van Hinsbergh V.W., Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 2008, 78:203-212.
122. Bignon M., Pichol-Thievend C., Hardouin J., Malbouyres M., Brechot N., Nasciutti L., Barret A., Teillon J., Guillon E., Etienne E., Caron M., Joubert-Caron R., Monnot C., Ruggiero F., Muller L., Germain S. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. Blood 2011, 118:3979-3989.
123. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97:1093-1107.
124. Myers K.A., Applegate K.T., Danuser G., Fischer R.S., Waterman C.M. Distinct ECM mechanosensing pathways regulate microtubule dynamics to control endothelial cell branching morphogenesis. J. Cell Biol. 2011, 192:321-334.
125. Adair-Kirk T.L., Senior R.M. Fragments of extracellular matrix as mediators of inflammation. Int. J. Biochem. Cell Biol. 2008, 40:1101-1110.
126. Sorokin L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 2010, 10:712-723.
127. Houghton A.M., Quintero P.A., Perkins D.L., Kobayashi D.K., Kelley D.G., Marconcini L.A., Mecham R.P., Senior R.M., Shapiro S.D. Elastin fragments drive disease progression in a murine model of emphysema. J. Clin. Invest. 2006, 116:753-759.
128. Weathington N.M., van Houwelingen A.H., Noerager B.D., Jackson P.L., Kraneveld A.D., Galin F.S., Folkerts G., Nijkamp F.P., Blalock J.E. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat. Med. 2006, 12:317-323.
129. Franco C., Britto K., Wong E., Hou G., Zhu S.N., Chen M., Cybulsky M.I., Bendeck M.P. Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis. Circ. Res. 2009, 105:1141-1148.
130. Wang S., Voisin M.B., Larbi K.Y., Dangerfield J., Scheiermann C., Tran M., Maxwell P.H., Sorokin L., Nourshargh S. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J. Exp. Med. 2006, 203:1519-1532.
131. Adler B., Ashkar S., Cantor H., Weber G.F. Costimulation by extracellular matrix proteins determines the response to TCR ligation. Cell. Immunol. 2001, 210:30-40.
132. Bartholomaus I., Kawakami N., Odoardi F., Schlager C., Miljkovic D., Ellwart J.W., Klinkert W.E., Flugel-Koch C., Issekutz T.B., Wekerle H., Flugel A. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
133. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864.
134. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
135. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 2007, 8:74-83.
136. Gill B.J., West J.L. Modeling the tumor extracellular matrix: tissue engineering tools repurposed towards new frontiers in cancer biology. J. Biomech. 2014, 47:1969-1978.
137. Moll C., Reboredo J., Schwarz T., Appelt A., Schurlein S., Walles H., Nietzer S. Tissue Engineering of a Human 3D in Vitro Tumor Test System 2013, Journal of visualized experiments, JoVE.
138. Phan-Lai V., Florczyk S.J., Kievit F.M., Wang K., Gad E., Disis M.L., Zhang M. Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. Biomacromolecules 2013, 14:1330-1337.
139. Mitra M., Mohanty C., Harilal A., Maheswari U.K., Sahoo S.K., Krishnakumar S. A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol. Vis. 2012, 18:1361-1378.
140. Hutmacher D.W., Horch R.E., Loessner D., Rizzi S., Sieh S., Reichert J.C., Clements J.A., Beier J.P., Arkudas A., Bleiziffer O., Kneser U. Translating tissue engineering technology platforms into cancer research. J. Cell. Mol. Med. 2009, 13:1417-1427.
141. Kim Y.J., Bae H.I., Kwon O.K., Choi M.S. Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test. Int. J. Biol. Macromol. 2009, 45:65-71.
142. Poh P.S., Hutmacher D.W., Stevens M.M., Woodruff M.A. Fabrication and in vitro characterization of bioactive glass composite scaffolds for bone regeneration. Biofabrication 2013, 5:045005.
143. Mohan N., Gupta V., Sridharan B., Sutherland A., Detamore M.S. The potential of encapsulating 'raw materials' in 3D osteochondral gradient scaffolds. Biotechnol. Bioeng. 2014, 111:829-841.
144. Cirillo V., Guarino V., Ambrosio L. Design of bioactive electrospun scaffolds for bone tissue engineering. J. Appl. Biomater. Funct. Mater. 2012, 10:223-228.
145. Infanger D.W., Lynch M.E., Fischbach C. Engineered culture models for studies of tumor-microenvironment interactions. Annu. Rev. Biomed. Eng. 2013, 15:29-53.
146. Dhandayuthapani B., Yoshida Y., Maekawa T., Kumar D.S. Polymeric scaffolds in tissue engineering application: a review. Int. J. Polym. Sci. 2011, 2011:19.
147. Coutu D.L., Yousefi A.M., Galipeau J. Three-dimensional porous scaffolds at the crossroads of tissue engineering and cell-based gene therapy. J. Cell. Biochem. 2009, 108:537-546.
148. Sahoo S.K., Panda A.K., Labhasetwar V. Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells. Biomacromolecules 2005, 6:1132-1139.
149. Horning J.L., Sahoo S.K., Vijayaraghavalu S., Dimitrijevic S., Vasir J.K., Jain T.K., Panda A.K., Labhasetwar V. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol. Pharm. 2008, 5:849-862.
150. Haroun A.A., Abo-Zeid M.A., Youssef A.M., Gamal-Eldeen A. In vitro biological study of gelatin/PLG nanocomposite using MCF-7 breast cancer cells. J. Biomed. Mater. Res. A 2013, 101:1388-1396.
151. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
152. Zhang M., Boughton P., Rose B., Lee C.S., Hong A.M. The use of porous scaffold as a tumor model. Int. J. Biomater. 2013, 2013:396056.
153. Karande T.S., Ong J.L., Agrawal C.M. Diffusion in musculoskeletal tissue engineering scaffolds: design issues related to porosity, permeability, architecture, and nutrient mixing. Ann. Biomed. Eng. 2004, 32:1728-1743.
154. Malda J., Woodfield T.B., van der Vloodt F., Kooy F.K., Martens D.E., Tramper J., van Blitterswijk C.A., Riesle J. The effect of PEGT/PBT scaffold architecture on oxygen gradients in tissue engineered cartilaginous constructs. Biomaterials 2004, 25:5773-5780.
155. Zhao F., Pathi P., Grayson W., Xing Q., Locke B.R., Ma T. Effects of oxygen transport on 3-d human mesenchymal stem cell metabolic activity in perfusion and static cultures: experiments and mathematical model. Biotechnol. Prog. 2005, 21:1269-1280.
156. Kellner K., Liebsch G., Klimant I., Wolfbeis O.S., Blunk T., Schulz M.B., Gopferich A. Determination of oxygen gradients in engineered tissue using a fluorescent sensor. Biotechnol. Bioeng. 2002, 80:73-83.
157. Lewis M.C., Macarthur B.D., Malda J., Pettet G., Please C.P. Heterogeneous proliferation within engineered cartilaginous tissue: the role of oxygen tension. Biotechnol. Bioeng. 2005, 91:607-615.
158. Volkmer E., Drosse I., Otto S., Stangelmayer A., Stengele M., Kallukalam B.C., Mutschler W., Schieker M. Hypoxia in static and dynamic 3D culture systems for tissue engineering of bone. Tissue Eng. A 2008, 14:1331-1340.
159. Carrier R.L., Rupnick M., Langer R., Schoen F.J., Freed L.E., Vunjak-Novakovic G. Effects of oxygen on engineered cardiac muscle. Biotechnol. Bioeng. 2002, 78:617-625.
160. Dunn J.C., Chan W.Y., Cristini V., Kim J.S., Lowengrub J., Singh S., Wu B.M. Analysis of cell growth in three-dimensional scaffolds. Tissue Eng. 2006, 12:705-716.
161. Park J., Berthiaume F., Toner M., Yarmush M.L., Tilles A.W. Microfabricated grooved substrates as platforms for bioartificial liver reactors. Biotechnol. Bioeng. 2005, 90:632-644.
162. Nishikawa M., Yamamoto T., Kojima N., Kikuo K., Fujii T., Sakai Y. Stable immobilization of rat hepatocytes as hemispheroids onto collagen-conjugated poly-dimethylsiloxane (PDMS) surfaces: importance of direct oxygenation through PDMS for both formation and function. Biotechnol. Bioeng. 2008, 99:1472-1481.
163. Nahmias Y., Kramvis Y., Barbe L., Casali M., Berthiaume F., Yarmush M.L. A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2006, 20:2531-2533.
164. Lin R.Z., Chang H.Y. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol. J. 2008, 3:1172-1184.
165. Sutherland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240:177-184.
166. Davey P., Tudhope G.R. Anticancer chemotherapy. Br. Med. J. (Clin. Res. Ed.) 1983, 287:110-113.
167. Friberg S., Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J. Surg. Oncol. 1997, 65:284-297.
168. dit Faute M.A., Laurent L., Ploton D., Poupon M.F., Jardillier J.C., Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin. Exp. Metastasis 2002, 19:161-168.
169. Abaza M., Luqmani Y.A. The influence of pH and hypoxia on tumor metastasis. Expert. Rev. Anticancer. Ther. 2013, 13:1229-1242.
170. Catalano V., Turdo A., Di Franco S., Dieli F., Todaro M., Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin. Cancer Biol. 2013, 23:522-532.
171. Willis A.L., Sabeh F., Li X.Y., Weiss S.J. Extracellular matrix determinants and the regulation of cancer cell invasion stratagems. J. Microsc. 2013, 251:250-260.
172. Fang H., Declerck Y.A. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013, 73:4965-4977.
173. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
174. Jinka R., Kapoor R., Sistla P.G., Raj T.A., Pande G. Alterations in cell-extracellular matrix interactions during progression of cancers. Int. J.Cell Biol. 2012, 2012:219196.
175. Harunaga J.S., Yamada K.M. Cell-matrix adhesions in 3D. Matrix Biol.: J. Int. Soc. Matrix Biol. 2011, 30:363-368.
176. Santos E., Garate A., Pedraz J.L., Orive G., Hernandez R.M. The synergistic effects of the RGD density and the microenvironment on the behavior of encapsulated cells: in vitro and in vivo direct comparative study. J Biomed Mater Res A 2013, (Epub ahead of print). 10.1002/jbm.a.35073.
177. Tome Y., Uehara F., Mii S., Yano S., Zhang L., Sugimoto N., Maehara H., Bouvet M., Tsuchiya H., Kanaya F., Hoffman R.M. 3-Dimensional tissue is formed from cancer cells in vitro on gelfoam(R), but not on matrigel. J. Cell. Biochem. 2014, 115:1362-1367.
178. Kleinman H.K., Martin G.R. Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol. 2005, 15:378-386.
179. Scarpa S., D'Orazi G., Modesti M., Modesti A. Ewing's sarcoma lines synthesize laminin and fibronectin. Virchows Archiv. A, Pathol. Anat. Histopathol. 1987, 410:375-381.
180. Scarpa S., Modesti A., Triche T.J. Extracellular matrix synthesis by undifferentiated childhood tumor cell lines. Am. J. Pathol. 1987, 129:74-85.
181. Stracca-Pansa V., Dickman P.S., Zamboni G., Bevilacqua P.A., Ninfo V. Extracellular matrix of small round cell tumors of childhood: an immunohistochemical study of 67 cases. Pediatr. Pathol./ Affiliated Int. Paediatr. Pathol. Assoc. 1994, 14:111-125.
182. Vijayakumar S., Liu G., Rus I.A., Yao S., Chen Y., Akiri G., Grumolato L., Aaronson S.A. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell 2011, 19:601-612.
183. Mendoza-Naranjo A., El-Naggar A., Wai D.H., Mistry P., Lazic N., Ayala F.R., da Cunha I.W., Rodriguez-Viciana P., Cheng H., Tavares Guerreiro Fregnani J.H., Reynolds P., Arceci R.J., Nicholson A., Triche T.J., Soares F.A., Flanagan A.M., Wang Y.Z., Strauss S.J., Sorensen P.H. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol. Med. 2013, 5:1087-1102.
184. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., Chilvers E.R., Dransfield I., Donnelly S.C., Strieter R., Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5:662-668.
185. Zhang Y., Lu H., Dazin P., Kapila Y. Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase. J. Biol. Chem. 2004, 279:48342-48349.
186. Thibault R.A., Mikos A.G., Kasper F.K. Protein and mineral composition of osteogenic extracellular matrix constructs generated with a flow perfusion bioreactor. Biomacromolecules 2011, 12:4204-4212.
187. Hartman O., Zhang C., Adams E.L., Farach-Carson M.C., Petrelli N.J., Chase B.D., Rabolt J.F. Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model. Biomaterials 2010, 31:5700-5718.
188. Lee J., Yoo J.J., Atala A., Lee S.J. The effect of controlled release of PDGF-BB from heparin-conjugated electrospun PCL/gelatin scaffolds on cellular bioactivity and infiltration. Biomaterials 2012, 33:6709-6720.
189. Sreerekha P.R., Menon D., Nair S.V., Chennazhi K.P. Fabrication of fibrin based electrospun multiscale composite scaffold for tissue engineering applications. J. Biomed. Nanotechnol. 2013, 9:790-800.
190. Levorson E.J., Hu O., Mountziaris P.M., Kasper F.K., Mikos A.G. Cell-Derived Polymer/Extracellular Matrix Composite Scaffolds for Cartilage Regeneration, Part 2: Construct Devitalization and Determination of Chondroinductive Capacity 2013, Tissue engineering. Part C, Methods.
191. Levorson E.J., Santoro M., Kurtis Kasper F., Mikos A.G. Direct and indirect co-culture of chondrocytes and mesenchymal stem cells for the generation of polymer/extracellular matrix hybrid constructs. Acta Biomater. 2013, 10:1824-1835.
192. Liao J., Guo X., Grande-Allen K.J., Kasper F.K., Mikos A.G. Bioactive polymer/extracellular matrix scaffolds fabricated with a flow perfusion bioreactor for cartilage tissue engineering. Biomaterials 2010, 31:8911-8920.
193. Liao J., Guo X., Nelson D., Kasper F.K., Mikos A.G. Modulation of osteogenic properties of biodegradable polymer/extracellular matrix scaffolds generated with a flow perfusion bioreactor. Acta Biomater. 2010, 6:2386-2393.
194. Mountziaris P.M., Tzouanas S.N., Mikos A.G. Dose effect of tumor necrosis factor-alpha on in vitro osteogenic differentiation of mesenchymal stem cells on biodegradable polymeric microfiber scaffolds. Biomaterials 2010, 31:1666-1675.
195. Saraf A., Lozier G., Haesslein A., Kasper F.K., Raphael R.M., Baggett L.S., Mikos A.G. Fabrication of nonwoven coaxial fiber meshes by electrospinning. Tissue Eng. Part C Methods 2009, 15:333-344.
196. Woodruff M.A., Hutmacher D.W. The return of a forgotten polymer-polycaprolactone in the 21st century. Prog. Polym. Sci. 2010, 35:1217-1256.
197. Brown T.D., Dalton P.D., Hutmacher D.W. Direct writing by way of melt electrospinning. Adv. Mater. 2011, 23:5651-5657.
198. Reddy K., Cao Y., Zhou Z., Yu L., Jia S.F., Kleinerman E.S. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis 2008, 11:257-267.
199. Reddy K., Zhou Z., Schadler K., Jia S.F., Kleinerman E.S. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol. Cancer Res.: MCR 2008, 6:929-936.
200. Zhou Z., Stewart K.S., Yu L., Kleinerman E.S. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. Angiogenesis 2011, 14:125-133.
201. Yu L., Su B., Hollomon M., Deng Y., Facchinetti V., Kleinerman E.S. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Res. 2010, 70:1334-1343.
202. Stewart K.S., Kleinerman E.S. Tumor vessel development and expansion in Ewing's sarcoma: a review of the vasculogenesis process and clinical trials with vascular-targeting agents. Sarcoma 2011, 2011:165837.
203. Castillero-Trejo Y., Eliazer S., Xiang L., Richardson J.A., Ilaria R.L. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors. Cancer Res. 2005, 65:8698-8705.
204. Kovar H., Bernard A. CD99-positive "Ewing's sarcoma" from mouse-bone marrow-derived mesenchymal progenitor cells?. Cancer Res. 2006, 66:9786. (author reply 9786).
205. Riggi N., Suva M.L., De Vito C., Provero P., Stehle J.C., Baumer K., Cironi L., Janiszewska M., Petricevic T., Suva D., Tercier S., Joseph J.M., Guillou L., Stamenkovic I. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010, 24:916-932.
206. Torchia E.C., Jaishankar S., Baker S.J. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res. 2003, 63:3464-3468.
207. Toretsky J.A., Steinberg S.M., Thakar M., Counts D., Pironis B., Parente C., Eskenazi A., Helman L., Wexler L.H. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001, 92:2941-2947.
208. Monument M.J., Bernthal N.M., Randall R.L. Salient features of mesenchymal stem cells-implications for Ewing sarcoma modeling. Fron. Oncol. 2013, 3:24.
209. DuBois S.G., Marina N., Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 2010, 116:749-757.
210. Dahlin R.L., Gershovich J.G., Kasper F.K., Mikos A.G. Flow perfusion co-culture of human mesenchymal stem cells and endothelial cells on biodegradable polymer scaffolds. Ann. Biomed. Eng. 2013, 42:1381-1390.
211. Gershovich J.G., Dahlin R.L., Kasper F.K., Mikos A.G. Enhanced osteogenesis in cocultures with human mesenchymal stem cells and endothelial cells on polymeric microfiber scaffolds. Tissue Eng. A 2013, 19:2565-2576.
212. Strammiello R., Benini S., Manara M.C., Perdichizzi S., Serra M., Spisni E., Picci P., Scotlandi K. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm. Metab. Res. 2003, 35:675-684.
213. Gershovich J.G., Dahlin R.L., Kasper F.K., Mikos A.G. Enhanced osteogenesis in cocultures with human mesenchymal stem cells and endothelial cells on polymeric microfiber scaffolds. Tissue Eng. A 2013, 19:2565-2576.
214. Lehner M., Gotz G., Proff J., Schaft N., Dorrie J., Full F., Ensser A., Muller Y.A., Cerwenka A., Abken H., Parolini O., Ambros P.F., Kovar H., Holter W. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS ONE 2012, 7:e31210.
215. Suminoe A., Matsuzaki A., Hattori H., Koga Y., Hara T. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr. Transplant. 2009, 13:746-753.
216. Cho D., Shook D.R., Shimasaki N., Chang Y.H., Fujisaki H., Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:3901-3909.
217. Verhoeven D.H., de Hooge A.S., Mooiman E.C., Santos S.J., ten Dam M.M., Gelderblom H., Melief C.J., Hogendoorn P.C., Egeler R.M., van Tol M.J., Schilham M.W., Lankester A.C. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol. Immunol. 2008, 45:3917-3925.
218. Ahn Y.O., Weigel B., Verneris M.R. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2010, 16:3819-3821.
219. Guo W., Guo Y., Tang S., Qu H., Zhao H. Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity. Clin. Orthop. Relat. Res. 2008, 466:2176-2183.
220. Evans C.H., Liu F., Porter R.M., O'Sullivan R.P., Merghoub T., Lunsford E.P., Robichaud K., Van Valen F., Lessnick S.L., Gebhardt M.C., Wells J.W. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:5341-5351.
221. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
222. Nichols J.E., Cortiella J. Engineering of a complex organ: progress toward development of a tissue-engineered lung. Proc. Am. Thorac. Soc. 2008, 5:723-730.
223. Nichols J.E., Niles J.A., Cortiella J. Design and development of tissue engineered lung: progress and challenges. Organogenesis 2009, 5:57-61.
224. Cortiella J., Niles J., Cantu A., Brettler A., Pham A., Vargas G., Winston S., Wang J., Walls S., Nichols J.E. Influence of acellular natural lung matrix on murine embryonic stem cell differentiation and tissue formation. Tissue Eng. A 2010, 16:2565-2580.
225. Ott H.C., Clippinger B., Conrad C., Schuetz C., Pomerantseva I., Ikonomou L., Kotton D., Vacanti J.P. Regeneration and orthotopic transplantation of a bioartificial lung. Nat. Med. 2010, 16:927-933.
226. Nichols J.E., Niles J., Riddle M., Vargas G., Schilagard T., Ma L., Edward K., La Francesca S., Sakamoto J., Vega S., Ogadegbe M., Mlcak R., Deyo D., Woodson L., McQuitty C., Lick S., Beckles D., Melo E., Cortiella J. Production and assessment of decellularized pig and human lung scaffolds. Tissue Eng. A 2013, 19:2045-2062.
227. Nichols J.E., Niles J.A., Vega S.P., Cortiella J. Novel in vitro respiratory models to study lung development, physiology, pathology and toxicology. Stem Cell Res. Ther. 2013, 4(Suppl. 1):S7.
228. Mishra D.K., Thrall M.J., Baird B.N., Ott H.C., Blackmon S.H., Kurie J.M., Kim M.P. Human lung cancer cells grown on acellular rat lung matrix create perfusable tumor nodules. Ann. Thorac. Surg. 2012, 93:1075-1081.
229. Szuhai K., Ijszenga M., de Jong D., Karseladze A., Tanke H.J., Hogendoorn P.C. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:2259-2268.
230. Burchill S.A. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J. Clin. Pathol. 2003, 56:96-102.
231. Kelleher F.C., Thomas D.M. Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin. Sarcoma Res. 2012, 2:6.
232. Subbiah V., Anderson P. Targeted therapy of Ewing's sarcoma. Sarcoma 2011, 2011:686985.
233. Owens C., Abbott L.S., Gupta A.A. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr. Drugs 2013, 15:473-492.